Grassroots vitamin d video alzheimer
![grassroots vitamin d video alzheimer grassroots vitamin d video alzheimer](http://blog.cytoplan.co.uk/wp-content/uploads/2021/03/GettyImages-1200548390-scaled.jpg)
We need to focus today not on developing future treatments for Alzheimer’s disease, but on raising public awareness of the fact that preventive efforts, well-documented in current peer-reviewed scientific literature, can have a dramatic impact, right now, in terms of reducing its incidence. Those who would be most enthusiastic about these seemingly forthright liaisons and monetary expenditures may be focused on the development of a blockbuster magic bullet for the treatment of Alzheimer’s disease for reasons that are less invested in alleviating suffering and more invested in financial outcome.
![grassroots vitamin d video alzheimer grassroots vitamin d video alzheimer](https://images-na.ssl-images-amazon.com/images/I/41OKehEnJhL._SX351_BO1,204,203,200_.jpg)
The reason we should temper our support for this announcement is because it represents a profound perversion of priority. Interestingly, those receiving synthetic vitamin E actually showed a positive response. But it doesn’t factor in the emotional expense borne by the family members of Alzheimer’s patients whose lives are irreparably compromised by this disease.ĭrug companies, as the Times article reported, “… have invested staggering amounts of money in developing drugs to treat Alzheimer’s disease, for example, but again and again the medications have failed in testing.” Just last month the New England Journal of Medicine reported that two of the latest candidates for treating Alzheimer’s disease had failed, miserably, to provide any meaningful benefit.Įven more disturbing was the recent report in the Journal of the American Medical Association demonstrating that the Alzheimer’s drug memantine, currently FDA approved for the “treatment” of moderate to severe Alzheimer’s disease was not only ineffective, but actually was associated with more decline in Alzheimer’s patient’s functionality when compared to a placebo. To contextualize this figure, it represents about twice what is spent on caring for heart disease patients. While at first blush, this five-year, $230 million effort may seem noble, the ultimate motivation for this seemingly ecumenical event is suspect.Īlzheimer’s disease affects some 5.4 million Americans, and according to a recent report from the RAND Corporation, costs Americans in the neighborhood of $200 billion each year to care for those afflicted.
![grassroots vitamin d video alzheimer grassroots vitamin d video alzheimer](https://price-pottenger.org/wp-content/uploads/2019/03/Vol-4-No-4-Stop-Vitamin-D-Deficiency-Table-1_1.jpg)
Recently, The New York Times announced the creation of a partnership between the National Institutes of Health, 10 pharmaceutical companies and seven nonprofit organizations dedicated to the development of drugs to treat, among other things, Alzheimer’s disease.